Biotechnology

Elutia

Kevin Rakin Acquires Shares of Elutia Inc.

Elutia released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 15.62M, actual EPS USD -0.7299

Elutia released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 3.323 M (forecast USD 6.65 M), actual EPS USD -0.1909 (forecast USD -0.155)

Elutia to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 6.65 M, EPS USD -0.155

Elutia Inc. Unveils Breast Reconstruction Strategy and Sells Drug-Releasing Biobag

Elutia released FY2025 Q2 earnings on August 14 After-Market (EST), actual revenue USD 6.263 M (forecast USD 6.55 M), actual EPS USD -0.26 (forecast USD -0.17)

Elutia released FY2025 Semi-Annual Earnings on August 14 After-Market EST, with actual revenue of USD 5.699 M and EPS of USD -0.4683

Elutia to Release FY2025 Q2 Earnings on August 14 After-Market EST, Forecast Revenue USD 6.55 M, EPS USD -0.17

Elutia Inc. Stock Dips, Analysts Lower Target Price

Lake Street Maintains Elutia's Buy Rating, Adjusts Target Price to $8

Elutia released FY2025 Q1 earnings on May 8 After-Market (EST), actual revenue USD 6.03 M (forecast USD 6.65 M), actual EPS USD -0.2099 (forecast USD -0.205)

Elutia Inc Expected to Report Quarterly Loss of 20 Cents Per Share

Elutia to Release FY2025 Q1 Earnings on May 8 After-Market EST, Forecast Revenue USD 6.65 M, EPS USD -0.205

Elutia Inc. CSO to speak at Chardan Conference

Elutia Inc. Launches EluPro Registration Study

Elutia Inc. Short Positions Decrease by 30.1%, Analyst Maintains Buy Rating

Elutia released FY2024 Q4 earnings on March 6 After-Market (EST), actual revenue 5.468 M USD (forecast 5.9 M USD), actual EPS -0.2608 USD (forecast -0.25 USD)

Elutia released FY2024 Annual Earnings on March 6 After-Market (EST), actual revenue $24.38M (forecast $24.8M), actual EPS -$1.8557 (forecast -$1.83)

Elutia to Release FY2024 Q4 Earnings on March 6, 2025, After-Market EST; Forecasted Revenue: 5.9 M USD, EPS: -0.25 USD

Elutia released FY2024 Q3 earnings on November 14 After-Market EST, actual revenue USD 3.662 M (forecast USD 6.6 M), actual EPS USD -0.3309 (forecast USD -0.44)

Haoxin

Sidus Space

Autozi Internet Tech Global

Hycroft Mining

Jyong Biotech

Starfighters Space

Creative Media & Community Trust

Velo3D

Adeia

Surf Air Mobility

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap